03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
17:50 , Jun 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Obesity Mouse studies suggest inhibiting IDO could help treat obesity. In a mouse model of high-fat diet-induced obesity, systemic IDO knockout decreased white adipose tissue (WAT), liver and body weights, lipid levels in the liver...
01:38 , Jun 20, 2018 |  BioCentury  |  Finance

Iterating iTeos

With a new office in the U.S. and $75 million in fresh series B funding to support clinical development of at least two candidates, Belgian cancer company iTeos Therapeutics S.A. is considering a U.S. IPO...
18:02 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Genmab, Janssen discontinue Darzalex combo trials

Genmab A/S (CSE:GEN; Pink:GMXAY) said partner Janssen Biotech Inc. will discontinue two studies of Darzalex daratumumab in combination with different immune checkpoint inhibitors. The studies include the open-label, international Phase Ib/II CALLISTO/LUC2001 trial, which is evaluating...
05:12 , May 29, 2018 |  BC Extra  |  Clinical News

Genmab slides as Darzalex combo trials discontinued

Genmab A/S (CSE:GEN; Pink:GMXAY) sank DKK239.30 (20%) to DKK953.20 in Copenhagen on Monday after it said partner Janssen Biotech Inc. will discontinue two studies of Darzalex daratumumab in combination with different immune checkpoint inhibitors. The studies...
17:03 , May 25, 2018 |  BC Week In Review  |  Clinical News

Incyte, Merck report additional Phase III data of epacadostat combo for melanoma

Incyte Corp. (NASDAQ:INCY) and partner Merck & Co. Inc. (NYSE:MRK) reported additional data from the Phase III ECHO-301/KEYNOTE-252 trial to treat melanoma showing that first-line treatment with epacadostat plus PD-1 inhibitor Keytruda pembrolizumab led to...
19:07 , May 18, 2018 |  BC Week In Review  |  Company News

Genentech terminates NewLink collaboration for IDO, TDO inhibitors

NewLink Genetics Corp. (NASDAQ:NLNK) said in an SEC filing that the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) terminated the remaining portion of a 2014 research collaboration that covered the development of next-generation indoleamine 2,3-dioxygenase...
18:50 , May 4, 2018 |  BC Week In Review  |  Clinical News

Incyte 'downsizing' IDO1 program, ends some combo trials

Incyte Corp. (NASDAQ:INCY) said it is "downsizing" its program evaluating epacadostat, its indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. The company plans to halt enrollment of six pivotal trials of epacadostat in combination with anti-PD-1 mAbs Keytruda...
15:36 , May 4, 2018 |  BC Week In Review  |  Clinical News

BMS discontinues pair of IDO1, Opdivo combo trials

Bristol-Myers Squibb Co. (NYSE:BMY) discontinued two Phase III trials evaluating indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor BMS-986205 in combination with its PD-1 inhibitor Opdivo nivolumab, according to ClinicalTrials.gov. According to the website, the company cited that...
20:55 , May 1, 2018 |  BC Extra  |  Company News

Incyte 'downsizing' IDO1 program, ends some combo trials

Incyte Corp. (NASDAQ:INCY) reported 1Q18 earnings and said it is "downsizing" its program evaluating epacadostat, its indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. The company plans to halt enrollment of six pivotal trials of epacadostat in combination...